Loading patent…
AssigneesThe Trustees of the University of Pennsylvania, The Regents of the University of California
InventorsMikko Siurala, Carl H. June, Avery Posey, Antoni Ribas, Anusha Kalbasi
Estimating the term…
The present disclosure provides orthogonal chimeric cytokine receptor/orthogonal cytokine pairs and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising an orthogonal chimeric cytokine receptor (e.g., an oIL2R-IL9R chimeric receptor) and a chimeric antigen receptor (CAR) or a T cell receptor (TCR). The present disclosure further provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding an orthogonal cytokine (e.g., oIL2), as well as methods of using the modified cells and the vector for treating cancer in a subject in need thereof.
A system for selective activation of a receptor in a cell, the system comprising:
A method of treating cancer in a subject in need thereof, the method comprising:
A system for selective activation of a receptor in a cell, the system comprising:
A method of treating cancer in a subject in need thereof, the method comprising:
Dependencies are inferred from the claim text.